Boehringer, Cue Biopharma Partner on Autoimmune Disease Treatment

Boehringer Ingelheim has entered into a research collaboration and licensing agreement with Cue Biopharma to advance a potential new therapy for autoimmune and inflammatory diseases. 

The partnership will focus on the development and commercialisation of CUE-501, a preclinical product candidate designed to selectively deplete B cells.

Cue Biopharma is a clinical-stage biopharmaceutical company working on innovative biologics that engage and modulate disease-specific T cells. Its CUE-501 candidate targets a membrane protein found on B cells while also engaging virus-specific memory killer T cells. This dual action aims to reduce autoimmune and inflammatory activity with greater precision and potentially fewer side effects than current B cell-targeting therapies.

The collaboration will allow Boehringer Ingelheim to strengthen its research and development portfolio in autoimmune and inflammatory diseases—areas where effective treatment options remain limited, and patients often require multiple therapies to find relief.

As part of the agreement, Boehringer will use Cue Biopharma’s T-cell engager platform to further develop the candidate and explore additional bispecific molecules that target B cells in autoimmune conditions.

Cue Biopharma will receive an upfront payment of $12 million along with research support. The agreement includes potential milestone payments of up to $345 million, linked to research, development, and commercial progress. Royalties on net sales are also part of the deal.

The collaboration aims to validate Cue Biopharma’s proprietary Immuno-STAT™ platform and contribute to the development of a new class of targeted therapies for autoimmune diseases.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!